Min‐Che TungChia‐Yen LinYu‐Ching WenLun‐Ching ChangShun‐Fa YangMing‐Hsien Chien2026-02-052026-02-052024-1210.1111/jcmm.70264https://scholars.csmu.edu.tw/handle/123456789/5119<jats:title>ABSTRACT</jats:title><jats:p>Genetic variants of deregulated long noncoding RNAs (lncRNAs) have been implicated in tumorigenesis, cancer progression and cancer recurrence. Single‐nucleotide polymorphisms (SNPs) of the lncRNA cyclin‐dependent kinase inhibitor 2B antisense RNA 1 (<jats:italic>CDKN2B‐AS1</jats:italic>) have been associated with the risk and progression of various cancers; however, their role in prostate cancer (PCa) remains underexplored. In this case–control study, we investigated the associations of <jats:italic>CDKN2B‐AS1</jats:italic> expression levels and variants with PCa risk and progression. For this, five SNPs of <jats:italic>CDKN2B‐AS1</jats:italic>—rs564398, rs1333048, rs1537373, rs2151280 and rs8181047—were genotyped using a TaqMan allelic discrimination assay; data were collected from 695 patients with PCa and 695 healthy controls. Our findings revealed that, under a dominant model, patients with PCa carrying at least one minor C allele of rs1333048 exhibited an increased risk of developing tumours with high Gleason grades; this risk was particularly high in patients without biochemical recurrence. Data from the Genotype‐Tissue Expression database indicated upregulated <jats:italic>CDKN2B‐AS1</jats:italic> expression in the prostates of individuals carrying the polymorphic C allele of rs1333048. Genotype screening of rs1333048 in PCa cell lines showed that cells with at least one minor C allele had higher <jats:italic>CDKN2B‐AS1</jats:italic> levels than those with the AA genotype. Furthermore, data from The Cancer Genome Atlas indicated that higher <jats:italic>CDKN2B‐AS1</jats:italic> levels in PCa tissues were correlated with larger tumour sizes (T3 + T4), more lymph node metastasis (N1), higher Gleason scores and shorter progression‐free survival. In conclusion, the polymorphic variants of <jats:italic>CDKN2B‐AS1</jats:italic> at rs1333048 may modulate <jats:italic>CDKN2B‐AS1</jats:italic> expression, thus accelerating PCa progression.</jats:p>[SDGs]SDG3Associations of the Expression Levels and Risk Variants of <i>CDKN2B‐AS1</i> Long Noncoding <scp>RNA</scp> With the Susceptibility and Progression of Prostate Cancerjournal-article